NO20071591L - Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav. - Google Patents

Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.

Info

Publication number
NO20071591L
NO20071591L NO20071591A NO20071591A NO20071591L NO 20071591 L NO20071591 L NO 20071591L NO 20071591 A NO20071591 A NO 20071591A NO 20071591 A NO20071591 A NO 20071591A NO 20071591 L NO20071591 L NO 20071591L
Authority
NO
Norway
Prior art keywords
interleukin
methods
chimeric
mutein
antagonists
Prior art date
Application number
NO20071591A
Other languages
English (en)
Inventor
David C Boisvert
Malinda Longphre
Teresa M Wong
Sydney M Zaremba
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of NO20071591L publication Critical patent/NO20071591L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Kimæriske polypeptidantagonister som innbefatter et interleukin-4- (IL-4)-mutein bundet til et interleukin-9- (IL-9)-mutein er tilveiebrakt, og likeledes polynukleotider som koder for de kimæriske IL-4- og IL-9-muteinantagonister. Det er også tilveiebrakt metoder for anvendelse av de kimæriske muteinantagonister og kodende polypeptider til redusering eller hemming av en celles responsivitet overfor et cytokin så som IL-4, IL-9 og/eller interleukin-13. Metoder for anvendelse av preparatene til behandling av sykdommer så som lungesykdommer (feks. astma) er også tilveiebrakt.
NO20071591A 2004-09-22 2007-03-27 Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav. NO20071591L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61227504P 2004-09-22 2004-09-22
US11/026,396 US7635754B2 (en) 2004-09-22 2004-12-29 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
PCT/US2005/034388 WO2006036878A2 (en) 2004-09-22 2005-09-21 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same

Publications (1)

Publication Number Publication Date
NO20071591L true NO20071591L (no) 2007-06-21

Family

ID=36074534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071591A NO20071591L (no) 2004-09-22 2007-03-27 Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.

Country Status (12)

Country Link
US (2) US7635754B2 (no)
EP (1) EP1805198A4 (no)
JP (1) JP2008513518A (no)
KR (1) KR20070068396A (no)
AU (1) AU2005289639A1 (no)
BR (1) BRPI0516776A (no)
CA (1) CA2581469A1 (no)
IL (1) IL181898A (no)
NO (1) NO20071591L (no)
NZ (1) NZ553897A (no)
RU (1) RU2007114958A (no)
WO (1) WO2006036878A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541238A (ja) 2005-05-05 2008-11-20 アーキペラゴ ホールディングス インコーポレイテッド 値段が付けられていない注文のオークション及び転送
WO2006121687A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Reprice-to-block order
US7912775B1 (en) 2005-05-05 2011-03-22 Archipelago Holdings, Inc. Liquidity analysis system and method
WO2006121796A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Tracking liquidity order
US7873561B1 (en) 2005-05-05 2011-01-18 Archipelago Holdings, Inc. Method and system for maintaining an order on a selected market center with maximum price exemption parameter
CA2635996A1 (en) * 2006-01-11 2007-07-19 Aerovance, Inc. Methods and compositions for treating asthma in human and non human primates
WO2009009775A1 (en) * 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
US20190135911A1 (en) * 2016-04-26 2019-05-09 Five Prime Therapeutics, Inc. Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1)
JP2020511988A (ja) * 2017-03-31 2020-04-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー シンセカイン組成物及び使用方法
EP3530320B1 (en) * 2018-02-27 2023-11-15 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel il-4-/il-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
ES2249786T3 (es) * 1995-08-24 2006-04-01 Genaera Corporation Uso de un anticuerpo antiinterleuquina 9 para la preparacion de un medicamento para el tratamiento de asma.
CA2253942A1 (en) * 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
AU2003265866A1 (en) * 2002-09-03 2004-03-29 Vit Lauermann Targeted release
DE602004028007D1 (de) 2003-05-14 2010-08-19 Bayer Pharmaceuticals Corp Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren

Also Published As

Publication number Publication date
JP2008513518A (ja) 2008-05-01
NZ553897A (en) 2011-01-28
KR20070068396A (ko) 2007-06-29
IL181898A0 (en) 2007-07-04
US7635754B2 (en) 2009-12-22
IL181898A (en) 2011-04-28
US20100099618A1 (en) 2010-04-22
CA2581469A1 (en) 2006-04-06
US20060063236A1 (en) 2006-03-23
RU2007114958A (ru) 2008-10-27
WO2006036878A3 (en) 2009-04-09
BRPI0516776A (pt) 2008-09-23
AU2005289639A1 (en) 2006-04-06
EP1805198A4 (en) 2010-01-20
EP1805198A2 (en) 2007-07-11
WO2006036878A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
NO20071591L (no) Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.
WO2002020767A3 (en) G-csf analog compositions and methods
NO20050749L (no) Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE602004023725D1 (de) Muteine von tränen-lipocalin
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
DE60126265D1 (de) Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
EA201070129A1 (ru) Фармацевтический сухой порошкообразный аэрозольный состав, включающий полипептид, и способ его приготовления
BRPI0212919B8 (pt) "muteínas da lipocalina associada à gelatinase de neutrófilos humanos, proteínas relacionadas, composição farmacêutica, método para geração e uso das mesmas".
NO20052894L (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20063375L (no) Agonist-anti-trkC-antistoffer og fremgangsmater for a anvende disse
DE112005000942A5 (de) Modulare Vorrichtung zur Befeuchtung von Atemgas
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
ATE490984T1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
AU2003257980A8 (en) Respiratory analyzer for exercise use
BRPI0410495A (pt) composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento
DK1790720T3 (da) Polypeptid med aktivitet af umættende omega3-fedtsyre, polynukleotid der koder for polypeptidet og anvendelse deraf
ATE447584T1 (de) Verfahren zur gewinnung von biologisch aktivem humanen g-csf aus inclusion bodies
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
DK1651270T3 (da) Medikamenter til inhalation omfattende betamimetika og et anticholinergikum
EP1527178A4 (en) NEW CLASS II CYTOKIN RECEPTORS AND ITS USES
DK1808179T3 (da) Anvendelse af HSP20 til fremme af sårheling og/eller til formindskelse af ardannelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application